Just 61.4% were up-to-date in 2023.<\/span><\/p>\nAccording to Kreimer and colleagues, emerging data suggest a single dose \u2014 which WHO has recommended in an effort to increase coverage \u2014 may provide protection, although they said whether it would provide similar protection to two doses \u201cuncertain.\u201d<\/p>\n
To assess the effectiveness of one vs. two doses, the researchers enrolled 20,330 girls aged 12 to 16 years and randomly assigned them in a 1:1:1:1 ratio to receive one or two doses of a bivalent HPV vaccine or one or two doses of a nonavalent HPV vaccine. According to the study, the researchers followed study participants for 5 years to track new HPV16 or HPV18 infections occurring from month 12 to month 60 and persisting for at least 6 months.<\/p>\n
Results showed that one dose of the bivalent vaccine was 98.2% (95% CI, 96.1%-99.6%) effective and one dose of the nonvalent vaccine was 97% (95% CI, 94.3%-99.1%) effective vs. two doses of either vaccine (97.8% and 98.5% effective, respectively). <\/p>\n
Additionally, although the trial was not meant to evaluate safety, the researchers noted that no safety concerns were identified, with just seven of the more than 20,000 participants reporting serious adverse events \u201cpossibly, probably or definitely\u201d related to the HPV vaccination over the 5-year study period.<\/p>\n
In an\u00a0accompanying\u00a0Ruanne V. Barnabas, MB, ChB, DPhil,<\/b> of Massachusetts General Hospital and Harvard Medical School, said the findings were \u201cthe strongest evidence to date\u201d to support the WHO recommendation that girls and young women up to age 20 get one or two doses of the HPV vaccine.<\/p>\n
\u201cThe WHO strategy for cervical cancer elimination sets ambitious but achievable targets: 90% of girls fully vaccinated with the HPV vaccine by 15 years of age, 70% of adult <\/span>women screened with a high-performance test, and 90% of women with disease receiving appropriate treatment,\u201d Barnabas wrote, adding that one-dose vaccination strengthens efforts made to meet these goals. <\/p>\n\u201cWe have the evidence and tools to eliminate cervical cancer. What remains is the collective will to implement them equitably, effectively and now,\u201d she wrote.<\/p>\n
\n
\n
Published by:<\/span>\n
Sources\/Disclosures<\/h3>\n Source: <\/h2>\n \nKreimer AR, et al. N Engl J Med. <\/i>2025;doi:10.1056\/NEJMoa2506765.\n<\/p>\nReferences:<\/h2>\n\n
Disclosures: <\/strong>
<\/p>\n
\n
\n
<\/p>\n
Ask a clinical question<\/strong> and tap into Healio AI’s knowledge<\/strong> base.<\/p>\n
<\/p>\nPubMed, enrolling\/recruiting trials, guidelines<\/li>\n
<\/p>\n
Clinical Guidance, Healio CME, FDA news<\/li>\n
<\/p>\n
Healio’s exclusive daily news coverage of clinical data<\/li>\n
\n <\/ul>\n
Learn more<\/button>\n <\/div>\n<\/div>\n
![\"infectious](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/idn.svg?la=en&h=19&w=171&hash=E5D33CE188190E773BF16C8B389C7AAC\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n